- World Pharma News Home » Clinical Trials » Boehringer Ingelheim announces commitment to progressing science with the Bouquet Studies
(a free service delivered by FeedBurner)
Data announced at the American College of Obstetricians and Gynaecologists (ACOG) annual clinical meeting suggest that up to one in ten women are suffering from a condition called hypoactive sexual desire disorder (HSDD) with only a third of these seeking advice or help from their healthcare professional.[1] HSDD is a highly prevalent, yet under-diagnosed, medical condition that can have a serious, detrimental effect on women’s quality of life, causing significant psychological distress and negatively impacting their relationships with their partners.[2,3]
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments